Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Blueprint Genetics | RCV000788424 | SCV000927524 | likely pathogenic | not provided | 2019-03-05 | criteria provided, single submitter | clinical testing | |
| Clinical Genetics and Genomics, |
RCV000788424 | SCV001450213 | likely pathogenic | not provided | 2017-12-04 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV003166077 | SCV003856835 | likely pathogenic | Cardiovascular phenotype | 2022-12-30 | criteria provided, single submitter | clinical testing | The c.58445_58457del13 variant, located in coding exon 153 of the TTN gene, results from a deletion of 13 nucleotides at nucleotide positions 58445 to 58457, causing a translational frameshift with a predicted alternate stop codon (p.P19482Qfs*12). This exon is located in the A-band region of the N2-B isoform of the titin protein and is constitutively expressed in TTN transcripts (percent spliced in or PSI 100%). This variant (referred to as c.59021_59033del) has been detected in a dilated cardiomyopathy cohort (Haas J et al. Eur Heart J, 2015 May;36:1123-35a). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. While truncating variants in TTN are present in 1-3% of the general population, truncating variants in the A-band are the most common cause of dilated cardiomyopathy (DCM) (Herman DS et al. N. Engl. J. Med., 2012 Feb;366:619-28; Roberts AM et al. Sci Transl Med, 2015 Jan;7:270ra6). TTN truncating variants encoded in constitutive exons (PSI >90%) have been found to be significantly associated with DCM regardless of their position in titin (Schafer S et al. Nat. Genet., 2017 01;49:46-53). Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Invitae | RCV003768471 | SCV004569564 | likely pathogenic | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2023-10-03 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Pro28547Glnfs*12) in the TTN gene. While this is not anticipated to result in nonsense mediated decay, it is expected to create a truncated TTN protein. This variant is present in population databases (rs762286447, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with TTN-related conditions (PMID: 33726816). This variant is also known as p.Pro25979Glnfs*12. ClinVar contains an entry for this variant (Variation ID: 636561). This variant is located in the A band of TTN (PMID: 25589632). Truncating variants in this region are significantly overrepresented in patients affected with dilated cardiomyopathy (PMID: 25589632). Truncating variants in this region have also been reported in individuals affected with autosomal recessive centronuclear myopathy (PMID: 23975875). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |